lymecycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives 1619 992-21-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lymecycline
  • mucomycin
  • ciclolysine
  • Tetracycline-L-methylenelysine
  • tetracyclinemethylenelysine
A semisynthetic antibiotic related to TETRACYCLINE. It is more readily absorbed than TETRACYCLINE and can be used in lower doses.
  • Molecular weight: 602.64
  • Formula: C29H38N4O10
  • CLOGP: -4.07
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 9
  • TPSA: 242.98
  • ALOGS: -2.66
  • ROTB: 10

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.100 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.629 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.345 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 1.679 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 81.710 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 62.240 % Moderate 0.65
herg hERG pIC50 4.643 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 1.416 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 3.296 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 84 % Moderate 0.65
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MTOR,NTRK1,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 66
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,STK33,SYK,TEK,TGFBR1 16
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.239 Moderate 0.65
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.169 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 5.176 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 79.700 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.767 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.65
pppb Pig plasma protein binding (% unbound) 79.740 % Moderate 0.65
rat-kpuu-brain Rat brain Kpuu 0.009 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 1.422 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.240 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 81.040 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 889.201 uM Moderate 0.65

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 60.68 36.45 20 754 42738 90584935
Hidradenitis 46.06 36.45 10 764 4337 90623336
Swelling face 44.78 36.45 19 755 81333 90546340
Dermatitis acneiform 37.11 36.45 9 765 6345 90621328

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Congenital nystagmus 37.92 36.63 5 396 95 42620839

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hidradenitis 52.68 32.42 12 1168 5168 110582951
Drug reaction with eosinophilia and systemic symptoms 49.98 32.42 22 1158 82073 110506046
Swelling face 44.41 32.42 21 1159 92300 110495819
Neurodevelopmental disorder 37.86 32.42 5 1175 84 110588035
Congenital nystagmus 36.62 32.42 5 1175 109 110588010
Dermatitis acneiform 33.19 32.42 10 1170 12685 110575434

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01AA04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
TETRACYCLINES
Tetracyclines
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35820 antiprotozoal drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:48001 protein synthesis inhibitor

Related Drugs by ATC class:

J01AA Tetracyclines 13 drugs
chlortetracyclineclomocyclinedemeclocyclinedoxycyclinemetacyclineminocyclineomadacyclineoxytetracyclinepenimepicyclinerolitetracyclinesarecyclinetetracycline show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.99 acidic
pKa2 3.72 acidic
pKa3 7.83 acidic
pKa4 9.46 acidic
pKa5 11.9 acidic
pKa6 13.04 acidic
pKa7 13.7 acidic
pKa8 10.16 Basic
pKa9 9.21 Basic
pKa10 8.44 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000167346 NUI
D06884 KEGG_DRUG
C0024200 UMLSCUI
CHEBI:59040 CHEBI
CHEMBL2103929 ChEMBL_ID
D008194 MESH_DESCRIPTOR_UI
DB00256 DRUGBANK_ID
10912 IUPHAR_LIGAND_ID
1679 INN_ID
7D6EM3S13P UNII
54707177 PUBCHEM_CID
6513 RXNORM
003993 NDDF
387548007 SNOMEDCT_US
96077007 SNOMEDCT_US

Pharmaceutical products:

None